SNFGE SNFGE
 
Thématique :
- Foie
Originalité :
Réexamen
Solidité :
Très solide
Doit faire évoluer notre pratique :
Immédiatement
 
 
Nom du veilleur :
Professeur Christine SILVAIN
Coup de coeur :
 
 
Hepatology
  2016/09  
 
  2016 Sep;64(3):908-22  
  doi: 10.1002/hep.28598  
 
  Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis  
 
  Gluud LL, Vilstrup H, Morgan MY  
  https://www.ncbi.nlm.nih.gov/pubmed/27081787  
 
 

Nonabsorbable disaccharides (NADs) have been used to treat hepatic encephalopathy (HE) since 1966. However, a Cochrane Review, published in 2004, found insufficient evidence to recommend their use in this context. This updated systematic review evaluates the effects of the NADs, lactulose and lactitol, for the treatment and prevention of HE in patients with cirrhosis. Thirty-eight randomized controlled trials, involving 1,828 patients, were identified through electronic and manual searches; 31 randomized controlled trials looked at the treatment of HE, while seven looked at its primary/secondary prevention. Random-effects meta-analyses showed that, compared to placebo/no intervention, NADs had a beneficial effect on HE (relative risk [RR] = 0.63, 95% confidence interval [CI] 0.53-0.74, number needed to treat [NNT] = 4) and serious liver-related adverse events such as liver failure, variceal bleeding, serious infections, spontaneous bacterial peritonitis, and hepatorenal syndrome (RR = 0.42, 95% CI 0.26-0.69, NNT = 50). Treatment was also associated with a reduction in mortality in patients with overt HE (RR = 0.36, 95% CI 0.14-0.94, NNT = 20), although not in patients with minimal HE. Meta-analyses of the prevention randomized controlled trials showed that NADs prevented the development of HE (RR = 0.47, 95% CI 0.33-0.68, NNT = 6), the risk of developing serious liver-related adverse events (RR = 0.48, 95% CI 0.33-0.70, NNT = 6), and reduced mortality (RR = 0.63, 95% CI 0.40-0.98, NNT = 20). Use of NADs was associated with nonserious gastrointestinal adverse events. There were no differences in the efficacy or safety of lactulose and lactitol.

CONCLUSIONS:

NADs have beneficial effects in the treatment and prevention of HE; their use, in this context, confers additional benefits including a reduction in serious liver-related morbidities and all-cause mortality. (Hepatology 2016;64:908-922).

 
Question posée
 
Revue et méta-analyse des disaccharides non absorbables dans le traitement et la prévention de l’encéphalopathie hépatique.
 
Question posée
 
Effet bénéfique sur l’encéphalopathie hépatique (RR=0,63) mais aussi sur la réduction des complications sévères liés à l’atteinte hépatique (hémorragies digestives par rupture de varices oesophagiennes, infections bactériennes sévères dont ascite et syndrome hépato-rénal).
 
Commentaires

Ne pas se priver d’utiliser le lactulose ou lactitol car que du bénéfice pour la survie des patients cirrhotiques.

 
www.snfge.org